Navigation Links
MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
Date:2/11/2009

VALENCIA, Calif., Feb. 11 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2008 fourth quarter financial results on Tuesday, February 17, 2009.

Management of the Company will host a conference call to discuss the fourth quarter financial results, clinical progress and other Company developments at 4:00 p.m. ET on Tuesday, February 17, 2009. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Matthew Pfeffer and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in listening to the conference call live via the internet may do so by visiting the Company's website at http://www.mannkindcorp.com. The web site replay will be available for 14 days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (800) 756-2759 or (402) 998-0791.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in Phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to email alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts certain other information to the website.


'/>"/>
SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
2. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
3. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
4. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
5. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
6. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
7. MannKind to Present at the UBS Global Life Sciences Conference
8. MannKind Corporation Reports Second Quarter Financial Results
9. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
10. MannKind to Present at Upcoming Conferences
11. MannKind Corporation Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) ... company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar Ataxia ... , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is estimated ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization for a ... image analysis. The re-branding components include a crisp, refreshed logo and a new ...
(Date:5/23/2016)... OXFORD, England , May 23, 2016 ... Wednesday, May 25 th at 10:15 a.m. ET before ... about the role genetically engineered mosquitos can play in controlling ... known carrier of the Zika virus.      (Logo: ... genetically engineered male mosquito with a self-limiting gene. Trials in ...
(Date:5/22/2016)... ... 22, 2016 , ... Doctors in Rome say micronutrients found in certain foods ... Surviving Mesothelioma has just posted an article on the new research. Click here ... Clinical Sciences and Translational Medicine evaluated more than 150 studies on polyphenols in cancer ...
Breaking Biology Technology:
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):